標(biāo)題: Titlebook: Atlas of Liquid Biopsy; Circulating Tumor Ce Ludmilla Thomé Domingos Chinen Book 2021 Springer Nature Switzerland AG 2021 Circulating tumor [打印本頁(yè)] 作者: Heel-Spur 時(shí)間: 2025-3-21 17:27
書(shū)目名稱Atlas of Liquid Biopsy影響因子(影響力)
書(shū)目名稱Atlas of Liquid Biopsy影響因子(影響力)學(xué)科排名
書(shū)目名稱Atlas of Liquid Biopsy網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Atlas of Liquid Biopsy網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Atlas of Liquid Biopsy被引頻次
書(shū)目名稱Atlas of Liquid Biopsy被引頻次學(xué)科排名
書(shū)目名稱Atlas of Liquid Biopsy年度引用
書(shū)目名稱Atlas of Liquid Biopsy年度引用學(xué)科排名
書(shū)目名稱Atlas of Liquid Biopsy讀者反饋
書(shū)目名稱Atlas of Liquid Biopsy讀者反饋學(xué)科排名
作者: 刪減 時(shí)間: 2025-3-21 21:20 作者: 震驚 時(shí)間: 2025-3-22 04:17
Circulating Tumor Cells in Colorectal Cancer,cers. It is a prevalent disease in older patients, but the incidence is rising in younger ones. The systemic therapy generally most used in metastatic CCR includes the basis of chemotherapy paired with a biological treatment. Usually, chemotherapy is composed of fluoropyrimidines combined with oxali作者: Cumulus 時(shí)間: 2025-3-22 05:05 作者: 過(guò)分自信 時(shí)間: 2025-3-22 12:34
Circulating Tumor Cells in Prostate Cancer,ld. In this scenario, prostate cancer has a predicted timeline natural evolution, from biochemical recurrence (PSA only increase) to evidence of metastasis in lymph nodes and bone to visceral disease. Also, biologically prostate cancer cells change from castration sensitive status to castration resi作者: 善辯 時(shí)間: 2025-3-22 15:22
Circulating Tumor Cells in Gastric Cancer,n cause of mortality. Exposure to many agents is associated with increased risk of developing GC, especially the infection by the Gram-negative bacteria ., which has been recognized as the most important factor leading to the development of gastric cancer. The cornerstone of localized GC treatment i作者: 吹牛需要藝術(shù) 時(shí)間: 2025-3-22 19:40 作者: 滔滔不絕地說(shuō) 時(shí)間: 2025-3-22 22:53
Circulating Tumor Microemboli: Characteristics and Clinical Relevance,ty is to control cancer, since it harbors heterogeneous characteristics and the processes, which are coordinated by a precise and well-organized machinery. The heterogeneity may be represented at many different levels: interpatient, intrapatient, and intratumoral. Additionally, the heterogeneity com作者: glans-penis 時(shí)間: 2025-3-23 02:11 作者: 全國(guó)性 時(shí)間: 2025-3-23 05:55 作者: 針葉類的樹(shù) 時(shí)間: 2025-3-23 11:38
,In Vitro and In Vivo Models of Circulating?Tumor Cells,ecent years. CTCs can function as potential real-time decision-making guides for selecting appropriate therapies during the course of the disease or for the development and testing of new treatments. However, these cells are extremely rare and require technology that is sensitive and specific enough作者: 館長(zhǎng) 時(shí)間: 2025-3-23 16:25 作者: Allure 時(shí)間: 2025-3-23 19:59 作者: 晚來(lái)的提名 時(shí)間: 2025-3-23 22:16 作者: antiandrogen 時(shí)間: 2025-3-24 03:20
Circulating Tumor Cells in Colorectal Cancer,platin and irinotecan. At the beginning of the formation and growth of a primary tumor, the cells are eliminated from the primary tumor and then circulate through the bloodstream, called circulating tumor cells (CTCs). In CCR, CTCs can be used for screening, in localized and metastatic cancer, which is explicated in this chapter.作者: 鞠躬 時(shí)間: 2025-3-24 06:44 作者: Harbor 時(shí)間: 2025-3-24 11:56
Circulating Tumor Cells in Prostate Cancer,an classical imaging evaluation (RECIST) in prostate cancer. This chapter summarizes and discusses the clinical results obtained in prostate cancer and clinical trials and the biological findings about cancer biology and metastasis that were obtained from CTC of prostate cancer.作者: Neuropeptides 時(shí)間: 2025-3-24 18:30 作者: LEVY 時(shí)間: 2025-3-24 19:27
https://doi.org/10.1007/978-3-319-00942-1h breast cancer, in addition to demonstrating and comparing the CellSearch system (approved by the Food and Drug Administration – FDA) and ISET? Technology – Rarecells (Isolation by SizE of Tumor Cells) used for the identification and cytopathological characterization of CTCs. Therefore, we can stat作者: 訓(xùn)誡 時(shí)間: 2025-3-25 02:27
https://doi.org/10.1007/978-3-319-00942-1ently of antibodies. This chapter is a review of studies involving CTCs of head and neck cancer and exposes the potential impact of CTCs on the prognosis of patients, the main clinical trials, and methodologies involving the topic.作者: 固定某物 時(shí)間: 2025-3-25 05:41 作者: 矛盾心理 時(shí)間: 2025-3-25 10:44
N. Sundararajan,P. Saratchandran,Yan Liprovements in overall survival compared to better supportive care, especially after a more comprehensive understanding of GC molecular biology. In addition, the use of chemotherapy and immunotherapy, after progression of the first-line treatment, was established by randomized studies. Circulating tu作者: 隱藏 時(shí)間: 2025-3-25 14:16 作者: Myocyte 時(shí)間: 2025-3-25 18:00
0.5-V MTCMOS/SOI Digital Circuits,g biological, functional, physical-chemical aspects of these – not so long ago unknown – group of cells, and the influence on tumor growth, failure in the systemic treatment, and consequently disease relapse or progression to metastasis. We will discuss all these topics here.作者: cognizant 時(shí)間: 2025-3-25 23:07
https://doi.org/10.1007/978-981-19-5759-8 response, and the important role TAMs play in metastasis. Macrophages as therapeutic targets will also be discussed. Finally, the concept that macrophages can physically interact with CTCs or fuse with tumor cells to create giant macrophages or cell fusions that are invisible to the immune system a作者: offense 時(shí)間: 2025-3-26 03:45 作者: lanugo 時(shí)間: 2025-3-26 05:43
CTCs in Solid Tumors. Clinical Applications of Circulating Tumor Cells in Breast Cancer,h breast cancer, in addition to demonstrating and comparing the CellSearch system (approved by the Food and Drug Administration – FDA) and ISET? Technology – Rarecells (Isolation by SizE of Tumor Cells) used for the identification and cytopathological characterization of CTCs. Therefore, we can stat作者: ACME 時(shí)間: 2025-3-26 11:30
Circulating Tumor Cells in Head and Neck Cancer,ently of antibodies. This chapter is a review of studies involving CTCs of head and neck cancer and exposes the potential impact of CTCs on the prognosis of patients, the main clinical trials, and methodologies involving the topic.作者: assent 時(shí)間: 2025-3-26 14:16
Circulating Tumor Cells in the context Non-small Cell Lung Cancer,To analyze the efficacy of treatment with ICIs and the somatic mutations in NSCLC, it is necessary to evaluate in real time, the changes that occur in tumor cells with the use of these therapies. However, it is difficult to perform this evaluation due to the invasive nature of conventional biopsy. C作者: 大范圍流行 時(shí)間: 2025-3-26 18:30 作者: 浮夸 時(shí)間: 2025-3-26 22:35
Circulating Tumor Cells in Mesenchymal Tumors,ies involving CTCs from mesenchymal tumors and mesenchymal-epithelial transition. It may open an area for future investigations and better understanding about CTCs and epithelial mesenchymal transition.作者: 鋼筆記下懲罰 時(shí)間: 2025-3-27 02:20
Circulating Tumor Microemboli: Characteristics and Clinical Relevance,g biological, functional, physical-chemical aspects of these – not so long ago unknown – group of cells, and the influence on tumor growth, failure in the systemic treatment, and consequently disease relapse or progression to metastasis. We will discuss all these topics here.作者: ETHER 時(shí)間: 2025-3-27 08:50
Giant Macrophages: Characteristics and Clinical Relevance, response, and the important role TAMs play in metastasis. Macrophages as therapeutic targets will also be discussed. Finally, the concept that macrophages can physically interact with CTCs or fuse with tumor cells to create giant macrophages or cell fusions that are invisible to the immune system a作者: 粘 時(shí)間: 2025-3-27 12:40
,In Vitro and In Vivo Models of Circulating?Tumor Cells,sed for preclinical evaluation medicines, identification of biomarkers, biological studies, and personalized medicinal strategies. In this chapter, we discuss the basic knowledge of CTCs and demonstrate some of the existing CTC-derived models, including in vivo CDXs and PDXs and in vitro functional 作者: 強(qiáng)壯 時(shí)間: 2025-3-27 17:08 作者: fatty-acids 時(shí)間: 2025-3-27 18:19
Book 2021nosis as a feasible tool. In this context, it is of the utmost importance to know the morphology and characteristics of CTCs to determine a correct diagnosis. Currently much of the scientific community is committed to expanding our knowledge of CTCs, and this work makes a valuable contribution, pres作者: 證明無(wú)罪 時(shí)間: 2025-3-27 23:22 作者: Cholecystokinin 時(shí)間: 2025-3-28 02:38 作者: Myofibrils 時(shí)間: 2025-3-28 09:42 作者: 網(wǎng)絡(luò)添麻煩 時(shí)間: 2025-3-28 12:55 作者: KEGEL 時(shí)間: 2025-3-28 17:45
N. Sundararajan,P. Saratchandran,Yan Licers. It is a prevalent disease in older patients, but the incidence is rising in younger ones. The systemic therapy generally most used in metastatic CCR includes the basis of chemotherapy paired with a biological treatment. Usually, chemotherapy is composed of fluoropyrimidines combined with oxali作者: anachronistic 時(shí)間: 2025-3-28 19:38
N. Sundararajan,P. Saratchandran,Yan Liy of LC (about 80–85%) is non-small cell (NSCLC), whose 5-year survival is about 50%, falling to 1% with the progress of the disease. The majority (80%) of diagnoses are late and with locally advanced disease (22%) or metastatic disease (57%), requiring chemotherapy and/or radiotherapy. The NSCLC is作者: 平項(xiàng)山 時(shí)間: 2025-3-29 02:30 作者: 歪曲道理 時(shí)間: 2025-3-29 03:21 作者: 非實(shí)體 時(shí)間: 2025-3-29 07:41 作者: SOB 時(shí)間: 2025-3-29 12:46
0.5-V MTCMOS/SOI Digital Circuits,ty is to control cancer, since it harbors heterogeneous characteristics and the processes, which are coordinated by a precise and well-organized machinery. The heterogeneity may be represented at many different levels: interpatient, intrapatient, and intratumoral. Additionally, the heterogeneity com作者: acrophobia 時(shí)間: 2025-3-29 15:32 作者: PANEL 時(shí)間: 2025-3-29 20:34 作者: 陰郁 時(shí)間: 2025-3-30 01:36 作者: NAVEN 時(shí)間: 2025-3-30 06:56 作者: 有抱負(fù)者 時(shí)間: 2025-3-30 09:16
Circulating Endothelial Cells: Characteristics and Clinical Relevance,ge number of physiological functions, such as homeostasis, endocrine, exocrine, structural and others, but also involved in clinical set. The knowledge about endothelial cells may encompass angiogenic inhibition therapy, and may be a promising anticancer treatment.作者: prostatitis 時(shí)間: 2025-3-30 13:29
Brief Summary and Perspectives for CTCs,this chapter, we intend to support that CTC analysis can involve heterogeneity and what is biologically emanated by the tumor. With technological help, unlocking the biological secrets of CTC population can stimulate the development of oncology and more alternatives and tests for treatment.作者: 溫順 時(shí)間: 2025-3-30 16:46
